An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington’s disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.
More: continued here
You must be logged in to post a comment.
All brands and product names are trademarked or registered trademarks of their respective companies
Copyright of syndicated content belongs to it’s respective author or news organization
Original content is Copyright © 2008
-
Channel 42
-
All Rights Reserved
Channel 42 is powered by Wordpress and a modified version of the High Tech theme
Part of the JD Web Publishing Network
-
Email:
